Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only.
INJ, NUGX, RNDR, and BONK shine in the cryptocurrency market, with NuggetRush’s presale nearing $1 million and Bonk’s 150% rally.
TLDR
Injective saw a 50% price rise this week, followed by Render’s 20% rally.
Bonk is the week’s top winner, soaring by 150%.
NuggetRush nears $1 million in presale sales and is tipped for a 65x rise after launch.
In this crypto week round-up, we’ll be discussing the week’s biggest winners, covering Injective (INJ), NuggetRush (NUGX), Render (RNDR), and Bonk (BONK). With further upsides, these tokens are altcoins to watch next week.
>> Buy NuggetRush Now <<
NuggetRush (NUGX): dominating ICO space
In the ICO market, where promising cryptocurrencies can be found, NuggetRush (NUGX) has emerged as the most dominant. The P2E memecoin experienced a strong surge in investor interest, almost hitting the $1 million fundraising milestone.
The rise in interest is due to its approach to cryptocurrency and advanced tokenomics. To begin, it combines play-to-earn (P2E), gamefi, impact gaming, and memes. This makes it stand out in the meme ecosystem and positions it for growth.
The upcoming game will be centered on gold mining. It promises to be thrilling and rewarding. While players enjoy an exciting gaming experience, they will also be granted valuable assets. More importantly, a share of in-game purchases and rewards will be dedicated to deserving causes, making the game meaningful and impactful.
Further, it has a low token supply of 500 million. This will play a crucial role in its price rise, making it one of the best cryptos to invest in. Additionally, there will be no buy-or-sell tax, which makes it even more appealing.
The presale is in its third round, and a token costs only $0.013. According to some analysts, there will be a 65x rise in its price after launch, positioning it as the best new crypto to invest in now.
>> Buy NuggetRush Now <<
Injective (INJ): creating new peaks
Injective (INJ) has been one of this year’s crypto marvels. The finance blockchain recently reached a new peak of $30.00 and doesn’t appear to stop anytime soon. In the past 7 days, Injective has registered a growth of over 50%, making it one of the week’s biggest winners.
Given its upside potential, Injective is one of the best coins to invest in. If you have yet to add some Injective crypto to your portfolio, now might be a great time.
Render (RNDR): significant price surge
Render (RNDR) is a blockchain-based project that aims to disrupt the computing and 3D graphics industries. Its features include offering affordable and high-quality rendering services. Similarly, Render is also one of the week’s biggest winners.
The token soared by over 20% this week, cementing its status as one of the market’s top crypto coins. The overall rise of the crypto market influenced its rally. At the time of writing, Render is trading at $4.21, aiming to end the year at $6.00.
Bonk (BONK): week’s biggest winner
Bonk (BONK) is the week’s biggest winner. The Solana-based memecoin has been gaining strong traction since the start of the final quarter. However, this week’s rally might be one of its biggest yet.
In the past 7 days, Bonk experienced a 150% rally and was over 900% up in the past 30 days. Its uptick has been influenced by the rise of Solana. More importantly, the recent listing of Bonk on Coinbase is the major catalyst for its gain this week.
While it is a good crypto to buy, analysts predict a price correction in the coming days. It remains to be seen how big of a drawback it will experience.
Conclusion
Following the staggering show of interest this week, Injective, NuggetRush, Render, and Bonk emerge as the biggest winners. With substantial room for growth, these are the altcoins to buy. All are offered on popular exchanges, and NuggetRush can be bought via the link below.
Visit NuggetRush Presale Website
Disclosure: This content is provided by a third party. crypto.news does not endorse any product mentioned on this page. Users must do their own research before taking any actions related to the company.
